MYLAN-CILAZAPRIL TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

CILAZAPRIL (CILAZAPRIL MONOHYDRATE)

Saadav alates:

MYLAN PHARMACEUTICALS ULC

ATC kood:

C09AA08

INN (Rahvusvaheline Nimetus):

CILAZAPRIL

Annus:

2.5MG

Ravimvorm:

TABLET

Koostis:

CILAZAPRIL (CILAZAPRIL MONOHYDRATE) 2.5MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0122806004; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2009-07-10

Toote omadused

_ _
_ _
_Page 1_
PRODUCT MONOGRAPH
PR MYLAN-CILAZAPRIL
Cilazapril
Monohydrate Tablets
1 mg, 2.5 mg, 5 mg
Angiotensin Converting Enzyme Inhibitor
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
Submission
Control No.: 257402
Date of Revision:
November 16, 2021
_ _
_ _
_Page 2_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
INDICATIONS AND CLINICAL USE
........................................................................
3
CONTRAINDICATIONS
............................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................
5
ADVERSE
REACTIONS............................................................................................12
DRUG INTERACTIONS
............................................................................................19
DOSAGE AND ADMINISTRATION
.........................................................................23
OVERDOSAGE
.........................................................................................................26
ACTION AND CLINICAL
PHARMACOLOGY.........................................................27
STORAGE AND STABILITY
....................................................................................30
SPECIAL HANDLING INSTRUCTIONS
...................................................................30
DOSAGE FORMS, COMPOSITION AND PACKAGING
..........................................30
PART II: SCIENTIFIC INFORMATION
..........................................................................
32
PHARMACEUTICAL INFORMATION
.....................................................................32
CLINICAL TRIALS
...................................................................................................33
DETAILED
PHARMACOLOGY..........................................